Molecular genetics of nicotine metabolism

Handbook of Experimental Pharmacology

Volumn 192, Issue , 2009, Pages 235-259

  Tyndale, Rachel F ^a   Mwenifumbo, Jill C ^b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 METHYLPYRAZOLE; 4 NITROPHENOL; ALDEHYDE OXIDASE; ALDEHYDE OXIDASE 1; ALPHA NAPHTHOFLAVONE; ANILINE; CLOTRIMAZOLE; CYTOCHROME P450; CYTOCHROME P450 2A13; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; DIETHYLDITHIOCARBAMIC ACID; DIMETHYLANILINE MONOOXYGENASE; ELLIPTICINE; ESTRADIOL; FLAVIN CONTAINING MONOOXYGENASE 3; GLUCURONOSYLTRANSFERASE; KETOCONAZOLE; METHOXSALEN; METYRAPONE; MICONAZOLE; NICOTINE; PROADIFEN; RALOXIFENE; TAMOXIFEN; TRANYLCYPROMINE; TRYPTAMINE; UNCLASSIFIED DRUG; COUMARIN 7 HYDROXYLASE; COUMARIN 7-HYDROXYLASE; NICOTINIC AGENT; UNSPECIFIC MONOOXYGENASE;

CIGARETTE SMOKING; ENZYME KINETICS; ENZYME METABOLISM; ENZYME REGULATION; EXPERIMENTAL ANIMAL; GENE CLUSTER; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIVER; MOLECULAR GENETICS; NONHUMAN; OXIDATION; PRIMATE; PRIORITY JOURNAL; REVIEW; ANIMAL; GENETICS; METABOLISM; MOUSE; RAT; SMOKING;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; MICE; NICOTINE; NICOTINIC AGONISTS; POLYMORPHISM, GENETIC; PRIMATES; RATS; SMOKING;

EID: 63849289214     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-69248-5_9     Document Type: Review

References (141)

1. Al-Salmy HS (2001) Individual variation in hepatic aldehyde oxidase activity. IUBMB Life 51:249-253
2. Al-Waiz M, Ayesh R, Mitchell SC, Idle JR, Smith RL (1988) Trimethylaminuria ('fish-odour syndrome'): a study of an affected family. Clin Sci 74:231-236
3. Audrain-McGovern J, Al Koudsi N, Rodriguez D, Wileyto EP, Shields PG, Tyndale RF (2007) The role of CYP2A6 in the emergence of nicotine dependence in adolescents. Pediatrics 119: e264-e274
4. Ayesh R, Al-Waiz M, Crothers MJ, Cholerton S, Mitchell SC, Idle JR, Smith RL (1988) Deficient nicotine N-oxidation in two sisters with trimethylaminuria. Br J Clin Pharmacol 25:664P-665P
5. Bao Z, He XY, Ding X, Prabhu S, Hong JY (2005) Metabolism of nicotine and cotinine by human cytochrome P450 2A13. Drug Metab Dispos 33:258-261
6. Benowitz NL, Jacob P 3rd (1985) Nicotine renal excretion rate influences nicotine intake during cigarette smoking. J Pharmacol Exp Ther 234:153-155
7. Benowitz NL, Jacob P 3rd (1994) Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther 56:483-493
8. Benowitz NL, Jacob P 3rd (2000) Effects of cigarette smoking and carbon monoxide on nicotine and cotinine metabolism. Clin Pharmacol Ther 67:653-659
9. Benowitz NL, Jacob P 3rd, Fong I, Gupta S (1994) Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 268:296-303
10. Benowitz NL, Perez-Stable EJ, Fong I, Modin G, Herrera B, Jacob P 3rd (1999) Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther 291:1196-1203
11. Benowitz NL, Griffin C, Tyndale R (2001) Deficient C-oxidation of nicotine continued. Clin Pharmacol Ther 70:567
12. Benowitz NL, Swan GE, Jacob P, 3rd, Lessov-Schlaggar CN, Tyndale RF (2006a) CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clin Pharmacol Ther 80:457-467
13. Benowitz NL, Lessov-Schlaggar CN, Swan GE, Jacob P 3rd (2006b) Female sex and oral contraceptive use accelerate nicotine metabolism. Clin Pharmacol Ther 79:480-488
14. Berger R, Mezey E, Clancy KP, Harta G, Wright RM, Repine JE, Brown RH, Brownstein M, Patterson D (1995) Analysis of aldehyde oxidase and xanthine dehydrogenase/oxidase as possible candidate genes for autosomal recessive familial amyotrophic lateral sclerosis. Somat Cell Mol Genet 21:121-131
15. Brandange S, Lindblom L (1979) The enzyme "aldehyde oxidase" is an iminium oxidase. Reaction with nicotine delta 1'(5') iminium ion. Biochem Biophys Res Commun 91:991-996
16. Byrd GD, Chang KM, Greene JM, deBethizy JD (1992) Evidence for urinary excretion of glucuronide conjugates of nicotine, cotinine, and trans-3'-hydroxycotinine in smokers. Drug Metab Dispos 20:192-197
17. Cashman JR, Park SB, Yang ZC, Wrighton SA, Jacob P, 3rd, Benowitz NL (1992) Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N'-oxide. Chem Res Toxicol 5:639-646
18. Cashman JR, Zhang J, Leushner J, Braun A (2001) Population distribution of human flavincontaining monooxygenase form 3: gene polymorphisms. Drug Metab Dispos 29:1629-1637
19. Cauffiez C, Lo-Guidice JM, Quaranta S, Allorge D, Chevalier D, Cenee S, Hamdan R, Lhermitte M, Lafitte JJ, Libersa C, Colombel JF, Stucker I, Broly F (2004) Genetic polymorphism of the human cytochrome CYP2A13 in a French population: implication in lung cancer susceptibility. Biochem Biophys Res Commun 317:662-669
20. Chang TK, Bandiera SM, Chen J (2003) Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels. Drug Metab Dispos 31:7-10
21. Chen G, Blevins-Primeau AS, Dellinger RW, Muscat JE, Lazarus P (2007) Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp > Tyr) polymorphism. Cancer Res 67:9024-9029
22. Daigo S, Takahashi Y, Fujieda M, Ariyoshi N, Yamazaki H, Koizumi W, Tanabe S, Saigenji K, Nagayama S, Ikeda K, Nishioka Y, Kamataki T (2002) A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics 12:299-306
23. Dalet-Beluche I, Boulenc X, Fabre G, Maurel P, Bonfils C (1992) Purification of two cytochrome P450 isozymes related to CYP2A and CYP3A gene families from monkey (baboon, Papio papio) liver microsomes. Cross reactivity with human forms. Eur J Biochem 204:641-648
24. Damaj MI, Siu EC, Sellers EM, Tyndale RF, Martin BR (2007) Inhibition of nicotine metabolism by methoxysalen: Pharmacokinetic and pharmacological studies in mice. J Pharmacol Exp Ther 320:250-257
25. Dempsey D, Tutka P, Jacob P, 3rd, Allen F, Schoedel K, Tyndale RF, Benowitz NL (2004) Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 76:64-72
26. Donato MT, Viitala P, Rodriguez-Antona C, Lindfors A, Castell JV, Raunio H, Gomez-Lechon MJ, Pelkonen O (2000) CYP2A5/CYP2A6 expression in mouse and human hepatocytes treated with various in vivo inducers. Drug Metab Dispos 28:1321-1326
27. Draper AJ, Madan A, Parkinson A (1997) Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Arch Biochem Biophys 341:47-61
28. Ekins S, VandenbrandenM, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV, Wrighton SA (1998) Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther 286:1253-1259
29. Fukami T, Nakajima M, Higashi E, Yamanaka H, McLeod HL, Yokoi T (2005a) A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity. Biochem Pharmacol 70:801-808
30. Fukami T, Nakajima M, Higashi E, Yamanaka H, Sakai H, McLeod HL, Yokoi T (2005b) Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity. Drug Metab Dispos 33:1202-1210
31. Fukami T, NakajimaM, Yamanaka H, Fukushima Y, McLeod HL, Yokoi T (2007) A novel duplication type of CYP2A6 gene in African-American population. Drug Metab Dispos 35:515-520
32. Fukushima-Uesaka H, Saito Y, Maekawa K, Saeki M, Kamatani N, Kajio H, Kuzuya N, Yasuda K, Sawada J (2006) Novel genetic variations and haplotypes of hepatocyte nuclear factor 4alpha (HNF4A) found in Japanese type II diabetic patients. Drug Metab Pharmacokinet 21:337-346
33. Garattini E,Mendel R, Romao MJ,Wright R, TeraoM(2003) Mammalian molybdo-flavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology. Biochem J 372:15-32 Gardner-Stephen D, Heydel JM, Goyal A, Lu Y, Xie W, Lindblom T, Mackenzie P, Radominska-Pandya A (2004) Human PXR variants and their differential effects on the regulation of human UDP-glucuronosyltransferase gene expression. Drug Metab Dispos 32:340-347
34. Ghosheh O, Hawes EM (2002) Microsomal N-glucuronidation of nicotine and cotinine: human hepatic interindividual, human intertissue, and interspecies hepatic variation. Drug Metab Dispos 30:1478-1483 Gu DF, Hinks LJ, Morton NE, Day IN (2000) The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. Ann Hum Genet 64:383-390
35. Haas DW (2006) Human genetic variability and HIV treatment response. Curr HIV/AIDS Rep 3:53-58
36. Haberl M, Anwald B, Klein K,Weil R, Fuss C, Gepdiremen A, Zanger UM, Meyer UA,Wojnowski L (2005) Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenet Genomics 15:609-624
37. Hakooz N, Hamdan I (2007) Effects of dietary broccoli on human in vivo caffeine metabolism: a pilot study on a group of Jordanian volunteers. Curr Drug Metab 8:9-15
38. Hammond DK, Bjercke RJ, Langone JJ, Strobel HW (1991) Metabolism of nicotine by rat liver cytochromes P-450. Assessment utilizing monoclonal antibodies to nicotine and cotinine. Drug Metab Dispos 19:804-808
39. He XY, Shen J, Hu WY, Ding X, Lu AY, Hong JY (2004) Identification of Val117 and Arg372 as critical amino acid residues for the activity difference between human CYP2A6 and CYP2A13 in coumarin 7-hydroxylation. Arch Biochem Biophys 427:143-153
40. Henningfield JE, Miyasato K, Jasinski DR (1985) Abuse liability and pharmacodynamic characteristics of intravenous and inhaled nicotine. J Pharmacol Exp Ther 234:1-12
41. Hernandez D, Janmohamed A, Chandan P, Phillips IR, Shephard EA (2004) Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters. Pharmacogenetics 14:117-130
42. Ho MK, Mwenifumbo JC, Zhao B, Gillam EM, Tyndale RF (2008) A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. Pharmacogenet Genomics 18:67-75
43. Hoffman SM, Hu S (2007) Dynamic evolution of the CYP2ABFGST gene cluster in primates. Mutat Res 616:133-138
44. Hoffman SM, Nelson DR, Keeney DS (2001) Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. Pharmacogenetics 11:687-698
45. Itoh M, Nakajima M, Higashi E, Yoshida R, Nagata K, Yamazoe Y, Yokoi T (2006) Induction of human CYP2A6 is mediated by the pregnane X receptor with peroxisome proliferator-activated receptor-gamma coactivator 1alpha. J Pharmacol Exp Ther 319:693-702
46. Iwahashi K,Waga C, Takimoto T (2004) Whole deletion of CYP2A6 gene (CYP2A6AST;4C) and smoking behavior. Neuropsychobiology 49:101-104
47. Jin CJ, Miners JO, Lillywhite KJ, Mackenzie PI (1993) cDNA cloning and expression of two new members of the human liver UDP-glucuronosyltransferase 2B subfamily. Biochem Biophys Res Commun 194:496-503
48. Kaipainen P, Nebert DW, Lang MA (1984) Purification and characterization of a microsomal cytochrome P-450 with high activity of coumarin 7-hydroxylase from mouse liver. Eur J Biochem 144:425-431
49. Kaivosaari S, Toivonen P, Hesse LM, Koskinen M, Court MH, Finel M (2007) Nicotine glucuronidation and the human UDP-glucuronosyltransferase UGT2B10. Mol Pharmacol Kim JH, Shin HD, Park BL, Cho YM, Kim SY, Lee HK, Park KS (2005) Peroxisome proliferatoractivated receptor gamma coactivator 1 alpha promoter polymorphisms are associated with early-onset type 2 diabetes mellitus in the Korean population. Diabetologia 48:1323-1330
50. Kitagawa K, Kunugita N, Kitagawa M, Kawamoto T (2001) CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. J Biol Chem 276:17830-17835
51. Kitamura S, Sugihara K, Ohta S (2006) Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab Pharmacokinet 21:83-98
52. Kiyotani K, Fujieda M, Yamazaki H, Shimada T, Guengerich FP, Parkinson A, Nakagawa K, Ishizaki T, Kamataki T (2002) Twenty one novel single nucleotide polymorphisms (SNPs) of the CYP2A6 gene in Japanese and Caucasians. Drug Metab Pharmacokinet 17:482-487
53. Krueger SK, Williams DE (2005) Mammalian flavin-containing monooxygenases: structure/ function, genetic polymorphisms and role in drug metabolism. Pharmacol Ther 106: 357-387
54. Kyerematen GA, Taylor LH, deBethizy JD, Vesell ES (1988a) Pharmacokinetics of nicotine and 12 metabolites in the rat. Application of a new radiometric high performance liquid chromatography assay. Drug Metab Dispos 16:125-129
55. Kyerematen GA, Owens GF, Chattopadhyay B, deBethizy JD, Vesell ES (1988b) Sexual dimorphism of nicotine metabolism and distribution in the rat. Studies in vivo and in vitro. Drug Metab Dispos 16:823-828
56. Kyerematen GA, Morgan M, Warner G, Martin LF, Vesell ES (1990) Metabolism of nicotine by hepatocytes. Biochem Pharmacol 40:1747-1756
57. Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, Fackenthal JD, Rogan PK, Ring B, Wrighton SA, Schuetz EG (2003) Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 307:906-922
58. Lamba J, Lamba V, Schuetz E (2005) Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr Drug Metab 6:369-383
59. Lang MA, Juvonen R, Jarvinen P, Honkakoski P, Raunio H (1989) Mouse liver P450Coh: genetic regulation of the pyrazole-inducible enzyme and comparison with other P450 isoenzymes. Arch Biochem Biophys 271:139-148
60. Lee AM, Miksys S, Tyndale RF (2006a) Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein. Br J Pharmacol 148:786-794
61. Lee AM, Miksys S, Palmour R, Tyndale RF (2006b) CYP2B6 is expressed in African Green monkey brain and is induced by chronic nicotine treatment. Neuropharmacology 50:441-450
62. Lee AM, Jepson C, Shields PG, Benowitz N, Lerman C, Tyndale RF (2007) CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev 16:1312-1314
63. Lim YP, Huang JD (2007) Pregnane X receptor polymorphism affects CYP3A4 induction via a ligand-dependent interaction with steroid receptor coactivator-1. Pharmacogenet Genomics 17:369-382
64. Lindberg RL, Juvonen R, Negishi M (1992) Molecular characterization of the murine Coh locus: an amino acid difference at position 117 confers high and low coumarin 7-hydroxylase activity in P450coh. Pharmacogenetics 2:32-37
65. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, Miners JO, Owens IS, Nebert DW (2005) Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15:677-685
66. Madan A, Graham RA, Carroll KM, Mudra DR, Burton LA, Krueger LA, Downey AD, Czerwinski M, Forster J, Ribadeneira MD, Gan LS, LeCluyse EL, Zech K, Robertson P, Jr., Koch P, Antonian L, Wagner G, Yu L, Parkinson A (2003) Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 31:421-431
67. Malaiyandi V, Sellers EM, Tyndale RF (2005) Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clin Pharmacol Ther 77:145-158
68. Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF (2006) Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry 11:400-409
69. Messina ES, Tyndale RF, Sellers EM (1997) A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 282:1608-1614
70. Meunier V, Bourrie M, Julian B, Marti E, Guillou F, Berger Y, Fabre G (2000) Expression and induction of CYP1A1/1A2, CYP2A6 and CYP3A4 in primary cultures of human hepatocytes: a 10-year follow-up. Xenobiotica 30:589-607
71. Miksys S, Tyndale RF (2004) The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. Drug Metab Rev 36:313-333
72. Miksys S, Hoffmann E, Tyndale RF (2000) Regional and cellular induction of nicotinemetabolizing CYP2B1 in rat brain by chronic nicotine treatment. Biochem Pharmacol 59: 1501-1511
73. Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF (2003) Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology 45:122-132
74. Minematsu N, Nakamura H, Furuuchi M, Nakajima T, Takahashi S, Tateno H, Ishizaka A (2006) Limitation of cigarette consumption by CYP2A6*4, *7 and *9 polymorphisms. Eur Respir J 27:289-292
75. Misra A, Hong JY, Kim S (2007) Multiplex genotyping of cytochrome p450 single-nucleotide polymorphisms by use of MALDI-TOF mass spectrometry. Clin Chem 53:933-939
76. Moon YJ, Zhang S, Brazeau DA, Morris ME (2007) Effects of the flavonoid biochanin A on gene expression in primary human hepatocytes and human intestinal cells. Mol Nutr Food Res 51:317-323
77. Munafo M, Clark T, Johnstone E, Murphy M, Walton R (2004) The genetic basis for smoking behavior: a systematic review and meta-analysis. Nicotine Tob Res 6:583-597
78. Murphy SE, Raulinaitis V, Brown KM (2005) Nicotine 5'-oxidation and methyl oxidation by P450 2A enzymes. Drug Metab Dispos 33:1166-1173
79. Mwenifumbo JC, Lessov-Schlaggar CN, Zhou Q, Krasnow RE, Swan GE, Benowitz NL, Tyndale RF (2007a) Identification of novel CYP2A6*1B Variants: The CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. Clin Pharmacol Ther 83:115-121
80. Mwenifumbo JC, Myers MG, Wall TL, Lin SK, Sellers EM, Tyndale RF (2005) Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. Pharmacogenet Genomics 15:189-192
81. Mwenifumbo JC, Sellers EM, Tyndale RF (2007b) Nicotine metabolism and CYP2A6 activity in a population of black African descent: Impact of gender and light smoking. Drug Alcohol Depend 89:24-33
82. Mwenifumbo JC, Al Koudsi N, Ho MK, Zhou Q, Hoffmann EB, Sellers EM, Tyndale RF (2008) Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Hum Mutat 29:679-688
83. Nagar S, Remmel RP (2006) Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene 25:1659-1672
84. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y (1996a) Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 24:1212-1217
85. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y (1996b) Characterization of CYP2A6 involved in 3'-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther 277:1010-1015
86. Nakajima M, Tanaka E, Kwon JT, Yokoi T (2002) Characterization of nicotine and cotinine N-glucuronidations in human liver microsomes. Drug Metab Dispos 30:1484-1490
87. Nakajima M, Fukami T, Yamanaka H, Higashi E, Sakai H, Yoshida R, Kwon JT, McLeod HL, Yokoi T (2006) Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 80:282-297
88. Nakayama H, Okuda H, Nakashima T, Imaoka S, Funae Y (1993) Nicotine metabolism by rat hepatic cytochrome P450s. Biochem Pharmacol 45:2554-2556
89. O'Loughlin J, Paradis G, Kim W, DiFranza J, Meshefedjian G, McMillan-Davey E, Wong S, Hanley J, Tyndale RF (2004) Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers. Tob Control 13:422-428
90. Obach (2004) Potent inhibiton of human liver aldehyde oxidase by raloxifene. DrugMetab Dispos, 32(1):89-97
91. Obach RS, Huynh P, Allen MC, Beedham C (2004) Human liver aldehyde oxidase: inhibition by 239 drugs. J Clin Pharmacol 44:7-19
92. Ohmori S, Shirakawa C, Motohashi K, Yoshida H, Abe H, Nakamura T, Horie T, Kitagawa H, Asaoka K, Rikihisa T, et al (1993a) Purification from liver microsomes from untreated cynomolgus monkeys of cytochrome P450 closely related to human cytochrome P450 2B6. Mol Pharmacol 43:183-190
93. Ohmori S, Horie T, Guengerich FP, Kiuchi M, Kitada M (1993b) Purification and characterization of two forms of hepatic microsomal cytochrome P450 from untreated cynomolgus monkeys. Arch Biochem Biophys 305:405-413 Oscarson M, McLellan RA, Gullsten H, Agundez JA, Benitez J, Rautio A, Raunio H, Pelkonen O, Ingelman-Sundberg M (1999) Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett 460:321-327
94. Oscarson M, McLellan RA, Asp V, Ledesma M, Bernal Ruiz ML, Sinues B, Rautio A, Ingelman- SundbergM(2002) Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum Mutat 20:275-283
95. Overby LH, Carver GC, Philpot RM (1997) Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans. Chem Biol Interact 106:29-45
96. Park SB, Jacob P 3rd, Benowitz NL, Cashman JR (1993) Stereoselective metabolism of (S)-(-)-nicotine in humans: formation of trans-(S)-(-)-nicotine N-1'-oxide. Chem Res Toxicol 6: 880-888
97. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM (2004) The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199:193-209
98. Peamkrasatam S, Sriwatanakul K, Kiyotani K, Fujieda M, Yamazaki H, Kamataki T, Yoovathaworn K (2006) In vivo evaluation of coumarin and nicotine as probe drugs to predict the metabolic capacity of CYP2A6 due to genetic polymorphism in Thais. Drug Metab Pharmacokinet 21: 475-484
99. Pearce R, Greenway D, Parkinson A (1992) Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. Arch Biochem Biophys 298:211-225
100. Pelkonen O, Sotaniemi EA, Ahokas JT (1985) Coumarin 7-hydroxylase activity in human liver microsomes. Properties of the enzyme and interspecies comparisons. Br J Clin Pharmacol 19: 59-66
101. Petersen DR, Norris KJ, Thompson JA (1984) A comparative study of the disposition of nicotine and its metabolites in three inbred strains of mice. Drug Metab Dispos 12:725-731
102. Pichard-Garcia L, Hyland R, Baulieu J, Fabre JM, Milton A, Maurel P (2000) Human hepatocytes in primary culture predict lack of cytochrome P-450 3A4 induction by eletriptan in vivo. Drug Metab Dispos 28:51-57
103. Pitarque M, Rodriguez-Antona C, Oscarson M, Ingelman-Sundberg M (2005) Transcriptional regulation of the human CYP2A6 gene. J Pharmacol Exp Ther 313:814-822
104. Poole A, Urwin C (1976) The metabolism of (14C)nicotine by isolated rhesus monkey hepatocytes in vitro. Biochem Pharmacol 25:281-283
105. Rao Y, Hoffmann E, Zia M, Bodin L, Zeman M, Sellers EM, Tyndale RF (2000) Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 58:747-755
106. Raunio H, Syngelma T, Pasanen M, Juvonen R, Honkakoski P, Kairaluoma MA, Sotaniemi E, Lang MA, Pelkonen O (1988) Immunochemical and catalytical studies on hepatic coumarin 7-hydroxylase in man, rat, and mouse. Biochem Pharmacol 37:3889-3895
107. Raunio H, Pokela N, Puhakainen K, Rahnasto M, Mauriala T, Auriola S, Juvonen RO (2008) Nicotine metabolism and urinary elimination in mouse: in vitro and in vivo. Xenobiotica 38: 34-47
108. Rodrigues AD (1994) Comparison of levels of aldehyde oxidase with cytochrome P450 activities in human liver in vitro. Biochem Pharmacol 48:197-200
109. Satarug S, Nishijo M, Ujjin P, Vanavanitkun Y, Baker JR, Moore MR (2004) Effects of chronic exposure to low-level cadmium on renal tubular function and CYP2A6-mediated coumarin metabolism in healthy human subjects. Toxicol Lett 148:187-197
110. Schoedel KA, Sellers EM, Palmour R, Tyndale RF (2003) Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. Mol Pharmacol 63:96-104
111. Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF (2004) Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics 14:615-626
112. Schulz TG, Thiel R, Neubert D, Brassil PJ, Schulz-Utermoehl T, Boobis AR, Edwards RJ (2001) Assessment of P450 induction in the marmoset monkey using targeted anti-peptide antibodies. Biochim Biophys Acta 1546:143-155
113. Seaton M, Kyerematen GA, Morgan M, Jeszenka EV, Vesell ES (1991) Nicotine metabolism in stumptailed macaques, Macaca arctoides. Drug Metab Dispos 19:946-954
114. Sellers EM, Kaplan HL, Tyndale RF (2000) Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin Pharmacol Ther 68:35-43
115. Shimada T, Yamazaki H, Guengerich FP (1996) Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica 26:395-403
116. Siu EC, Tyndale RF (2007) Characterization and comparison of nicotine and cotinine metabolism in vitro and in vivo in DBA/2 and C57BL/6 mice. Mol Pharmacol 71:826-834
117. Siu EC,Wildenauer DB, Tyndale RF (2006) Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. Psychopharmacology 184:401-408
118. Steinberg KK, Relling MV, Gallagher ML, Greene CN, Rubin CS, French D, Holmes AK, Carroll WL, Koontz DA, Sampson EJ, Satten GA (2007) Genetic studies of a cluster of acute lymphoblastic leukemia cases in Churchill County, Nevada. Environ Health Perspect 115:158-164
119. Strasser AA, Malaiyandi V, Hoffmann E, Tyndale RF, Lerman C (2007) An association of CYP2A6 genotype and smoking topography. Nicotine Tob Res 9:511-518
120. Su T, Bao Z, Zhang QY, Smith TJ, Hong JY, Ding X (2000) Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Cancer Res 60:5074-5079
121. Sugihara K, Kitamura S, Tatsumi K, Asahara T, Dohi K (1997) Differences in aldehyde oxidase activity in cytosolic preparations of human and monkey liver. Biochem Mol Biol Int 41: 1153-1160
122. Swan GE, Benowitz NL, Lessov CN, Jacob P 3rd, Tyndale RF, Wilhelmsen K (2005) Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenet Genomics 15:115-125
123. Sziraki, Lipovac MN, Hashim A, Sershen H, Allen D, Cooper T, Czobor P, Lajtha A (2001) Differences in nicotine-induced dopamine release and nicotine pharmacokinetics between Lewis and Fischer 344 rats. Neurochem Res 26:609-617
124. Tayama Y, Miyake K, Sugihara K, Kitamura S, Kobayashi M, Morita S, Ohta S, Kihira K (2007) Developmental changes of aldehyde oxidase activity in young Japanese children. Clin Pharmacol Ther 81:567-572
125. Thasler WE, Dayoub R, Muhlbauer M, Hellerbrand C, Singer T, Grabe A, Jauch KW, Schlitt HJ, Weiss TS (2006) Repression of cytochrome P450 activity in human hepatocytes in vitro by a novel hepatotrophic factor, augmenter of liver regeneration. J Pharmacol Exp Ther 316: 822-829
126. Treacy EP, Akerman BR, Chow LM, Youil R, Bibeau C, Lin J, Bruce AG, Knight M, Danks DM, Cashman JR, Forrest SM (1998) Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication. Hum Mol Genet 7:839-845
127. Wang H, Tan W, Hao B, Miao X, Zhou G, He F, Lin D (2003a) Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res 63:8057-8061
128. Wang H, Donley KM, Keeney DS, Hoffman SM (2003b) Organization and evolution of the Cyp2 gene cluster on mouse chromosome 7, and comparison with the syntenic human cluster. Environ Health Perspect 111:1835-1842
129. Wang J, Pitarque M, Ingelman-SundbergM(2006a) 3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression. Biochem Biophys Res Commun 340: 491-497
130. Wang SL, He XY, Shen J, Wang JS, Hong JY (2006b) The missense genetic polymorphisms of human CYP2A13: functional significance in carcinogen activation and identification of a null allelic variant. Toxicol Sci 94:38-45
131. WorthamM, Czerwinski M, He L, Parkinson A,Wan YJ (2007) Expression of CAR, HNF4{alpha}, and POR genes determine interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. Drug Metab Dispos 35:1700-1710
132. Xu C, Rao YS, Xu B, Hoffmann E, Jones J, Sellers EM, Tyndale RF (2002) An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochem Biophys Res Commun 290:318-324
133. Yamanaka H, Nakajima M, Nishimura K, Yoshida R, Fukami T, Katoh M, Yokoi T (2004) Metabolic profile of nicotine in subjects whose CYP2A6 gene is deleted. Eur J Pharm Sci 22:419-425
134. Yamanaka H, Nakajima M, Katoh M, Kanoh A, Tamura O, Ishibashi H, Yokoi T (2005a) Trans-3'- hydroxycotinine O- and N-glucuronidations in human liver microsomes. Drug Metab Dispos 33:23-30
135. Yamanaka H, Nakajima M, Fukami T, Sakai H, Nakamura A, Katoh M, Takamiya M, Aoki Y, Yokoi T (2005b) CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Drug Metab Dispos 33: 1811-1818
136. Yamano S, Tatsuno J, Gonzalez FJ (1990) The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29:1322-1329
137. Yamazaki H, Inoue K, HashimotoM, Shimada T (1999) Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol 73:65-70
138. Yang M, Kunugita N, Kitagawa K, Kang SH, Coles B, Kadlubar FF, Katoh T, Matsuno K, Kawamoto T (2001) Individual differences in urinary cotinine levels in Japanese smokers: relation to genetic polymorphism of drug-metabolizing enzymes. Cancer Epidemiol Biomarkers Prev 10:589-593
139. Yoshida R, Nakajima M, Nishimura K, Tokudome S, Kwon JT, Yokoi T (2003) Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 74:69-76
140. Zhang W, Kilicarslan T, Tyndale RF, Sellers EM (2001) Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metab Dispos 29:897-902
141. Zhang X, Su T, Zhang QY, Gu J, Caggana M, Li H, Ding X (2002) Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant. J Pharmacol Exp Ther 302:416-423